KYMR
Kymera Therapeutics
Stock NASDAQ – Stock Market Prices, News & Analysis
Kymera Therapeutics Inc se focalise sur la découverte et le développement de médicaments de thérapie ciblée pour la dégradation des protéines dans diverses maladies.
Kymera Therapeutics
KYMR
Kymera Therapeutics Inc se focalise sur la découverte et le développement de médicaments de thérapie ciblée pour la dégradation des protéines dans diverses maladies.
Price history of Kymera Therapeutics
Price history of Kymera Therapeutics
Performance & Momentum
Kymera Therapeutics Rises on Clinical Win, $602M Fundraise
Kymera Therapeutics (NASDAQ: KYMR) hit an all-time high following highly positive phase Ib clinical trial results of its atopic dermatitis treatment KT-621, demonstrating strong STAT6 degradation and broad clinical activity. This data sparked significant investor enthusiasm, driving four consecutive days of gains. Additionally, the company completed a $602 million capital raise by selling 7 million shares at $86 each, substantially strengthening its cash position for future development.
Similar stocks to Kymera Therapeutics
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
